You searched for Gout - Page 19 of 96

Abstract Number: 0650 • ACR Convergence 2020
Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout
Marco Ferrández-Jiménez¹, Irene Calabuig², Maria Luisa Peral², Miguel Gómez-Garberí¹ and Mariano Andrés², ¹Universidad Miguel Hernández de Elche, Alicante, Spain, ²Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain
Background/Purpose: Osteoporosis causes significant morbidity and mortality through the development of fragility fractures, including vertebral fractures (VF). Patients with gout may show an increased risk…
Abstract Number: 0651 • ACR Convergence 2020
Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares
Luigi Brunetti¹, Janaki Vekaria¹, Peter Lipsky² and Naomi Schlesinger³, ¹Rutgers Ernest Mario School of Pharmacy, piscataway, NJ, ²AMPEL BioSolutions LLC., Charlottesville, VA, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Gout is the most common inflammatory arthritis and its economic burden is substantial, with estimates for the overall cost exceeding $20 billion (US) annually.…
Abstract Number: 0652 • ACR Convergence 2020
Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout
Ruth Topless¹, Tony Merriman¹, Siamak Noorbaloochi² and Jasvinder Singh³, ¹University of Otago, Dunedin, New Zealand, ²University of Minnesota, Minneapolis, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Few studies, if any, have found association of the biochemical cause of gout (high serum urate) with functional limitation and health-related quality of life…
Abstract Number: 0653 • ACR Convergence 2020
Nutrient Content of Gout Flare Trigger Foods
Tanya Major¹, Ruth Topless¹, Elsa Sanchez-Lopez², Jennie Harré Hindmarsh³, Lisa Stamp⁴, Nicola Dalbeth⁵, Monica Guma⁶, Robert Terkeltaub⁷ and Tony Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of California San Diego, San Diego, CA, ³Ngāti Porou Hauora, Te Puia Springs, New Zealand, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of California San Diego, La Jolla, CA, ⁷VA/UCSD, San Diego, CA
Background/Purpose: A wide variety of foods are reported by patients to be triggers of gout flares. Some of these foods have been associated with serum…
Abstract Number: 0655 • ACR Convergence 2020
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial
Kristian Zobbe¹, Robin Christensen², Sabrina Mai Nielsen³, Lisa Stamp⁴, Marius Henriksen⁵, Anders Føhrby Overgaard⁶, Lene Dreyer⁷, Filip Krag Knop⁸, Jasvinder Singh⁹, Michael Doherty¹⁰, Pascal Richette¹¹, Arne Astrup¹², Karen Ellegaard¹, Else Marie Bartels¹³, Mikael Boesen¹⁴, Henrik Rindel Gudbergsen¹⁵, Henning Bliddal¹⁵ and Lars Erik Kristensen¹⁶, ¹The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, Denmark, ²Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark, ³The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Frederiksberg, Denmark, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, ⁶The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Sorø, ⁷Department of Rheumatology, Aalborg UnIversity Hospital, Aalborg, Denmark, ⁸Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, Copenhagen, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham UK, Nottingham, United Kingdom, ¹¹Department of Rheumatology, Lariboisière Hospital, Paris, France, ¹²Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark, ¹³Department of Neurology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Frederiksberg, Denmark, Copenhagen, Denmark, ¹⁴Department of Radiology Copenhagen University hospital Bispebjerg and Frederiksberg; The Parker Institute, Copenhagen, Denmark, ¹⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Frederiksberg, Denmark, ¹⁶The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Despite scarce evidence regarding the effects of weight loss in gout1, international guidelines recommend dietary advice and weight loss as a core management strategy…
Abstract Number: 0656 • ACR Convergence 2020
A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis
Philip Robinson¹, Nicola Dalbeth², Chris Frampton³, Tony Merriman³, Amanda Phipps-Green³ and Peter Donovan⁴, ¹University of Queensland, Herston, Queensland, Australia, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴Royal Brisbane & Women's Hospital, HERSTON, Queensland, Australia
Background/Purpose: Intake of sugar is associated with increased incident gout. Sugar taxes have been effective at reducing the intake of sugar in several jurisdictions. We…
Abstract Number: 0657 • ACR Convergence 2020
Gout and Heart Failure in the US
Gurkipal Singh¹, Maanek Sehgal² and Alka Mithal³, ¹Stanford University, Stanford, CA, ²UCLA, Los Angeles, CA, ³ICORE, Woodside, CA
Background/Purpose: Heart failure (HF) is the eighth leading cause of death in the US, with a 38% increase in the number of deaths due to…
Abstract Number: 0658 • ACR Convergence 2020
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
Blanka Stiburkova¹, Yu Toyoda², Katerina Pavelcova¹, Jana Bohata¹, Pavel Ješina³, Yu Kubota², Tappei Takada² and Hiroshi Suzuki², ¹Institute of Rheumatology, Prague, Czech Republic, ²Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, ³Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
Abstract Number: 0659 • ACR Convergence 2020
Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1
Megan Leask¹, Nicola Dalbeth², Lisa Stamp³, Tony Merriman⁴, Amanda Phipps-Green⁴, Ruth Topless⁴, James Boocock⁵, Hyon Choi⁶, Keresoma Leaupepe¹ and Eli Stahl⁷, ¹University of Otago, Dunedin, Otago, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago Christchurch, Christchurch, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁷Mt Sinai School of Medicine, New York, NY
Background/Purpose: Polynesian (NZ Māori and Pacific) populations have increased prevalence of gout. Hyperuricaemia is contributed to by increased urate production in the liver via the…
Abstract Number: 0660 • ACR Convergence 2020
Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin
Ana Beatriz Vargas-Santos¹, Christine Peloquin², Seoyoung Kim³ and Tuhina Neogi², ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, ²Boston University School of Medicine, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Sodium-glucose co-transporter-2 inhibitors (SGLT2-i) are anti-diabetic drugs that have a urate-lowering effect. SGLT2-i had a more favorable impact on gout risk than glucagon-like peptide-1…
Abstract Number: 0662 • ACR Convergence 2020
Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Alison Petro¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Gout is the most common type of inflammatory arthritis, with a prevalence in the Veteran’s Health Administration (VHA) of nearly 6%. While gout flares…
Abstract Number: 0663 • ACR Convergence 2020
Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation
Nicholas Sumpter¹, Murray Cadzow², Alexander So³, Richard Reynolds¹ and Tony Merriman², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Otago, Dunedin, New Zealand, ³University of Lausanne, Lausanne, Switzerland
Background/Purpose: This study aimed to estimate the extent to which gout associated genetic variants are associated with the presence/absence of common comorbidities in gout patients…
Abstract Number: 0667 • ACR Convergence 2020
Gout Management Beyond Prescription Writing: The Role of the Pharmacist
Emma Dorris¹, Paul Ryan², Mariosa Kieran³, Nicola Dalbeth⁴ and Geraldine McCarthy⁵, ¹School of Medicine, Dublin, Dublin, Ireland, ²Mayfield Family Practice, Cork, Cork, Ireland, ³Pharmacy Department, Dublin, Dublin, Ireland, ⁴University of Auckland, Auckland, New Zealand, ⁵University College Dublin, Dublin, Dublin, Ireland
Background/Purpose: Urate lowering therapy (ULT) is recommended for long-term gout management. However, gout flares are common at the time of starting ULT, and these flares…
Abstract Number: 0669 • ACR Convergence 2020
Calcium Pyrophosphate Crystal Deposition in Gouty Tophi
Hang-Korng Ea¹, Alan Gauffenic², Quand Nguyen³, Nhu Pham³, Oceane Olivier², Vincent Frochot⁴, Dominique Bazin⁵, Nghia Le³, Caroline Marty², Agnès Ostertag², Martine Cohen-Solal¹, Jean-Denis Laredo⁶, Pascal Richette⁷ and Thomas Bardin⁸, ¹Université de Paris, INSERM UMR 1132, BIOSCAR, AP-HP, DMU Locomoteur, Paris, France, ²Université de Paris, INSERM UMR 1132, BIOSCAR, Paris, France, ³Vien Gut Medical Center and French-Vietnamese research center on gout and chronic diseases, Ho Chi Ming, Vietnam, ⁴Hôpital Tenon, Service des explorations fonctionnelles multidisciplinaires, Sorbonne université, UMR_S1155, Paris, France, ⁵Institut de Chimie Physique, Université Paris-Saclay et CNRS - UMR8000, Orsay, France, ⁶AP-HP Université de Paris, Paris, ⁷Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, ⁸Université de Paris, INSERM U1132 and Hôpital Lariboisièe, Paris, France, Paris, France
Background/Purpose: The coexistence of calcium pyrophosphate (CPP) and monosodium urate crystals is rarely reported in gouty tophi. We investigated CPP crystal deposits in a series…
Abstract Number: 0670 • ACR Convergence 2020
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
Sara Tedeschi¹, Kazuki Yoshida¹, Weixing Huang² and Daniel H. Solomon¹, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Prior studies of calcium pyrophosphate crystal deposition disease (CPPD) epidemiology either focused on the entire spectrum of CPPD or identified patients with its acute…

Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout

Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares

Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout

Nutrient Content of Gout Flare Trigger Foods

Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial

A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis

Gout and Heart Failure in the US

Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations

Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1

Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin

Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study

Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation

Gout Management Beyond Prescription Writing: The Role of the Pharmacist

Calcium Pyrophosphate Crystal Deposition in Gouty Tophi

Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study

Simple Search Results